377 related articles for article (PubMed ID: 33394604)
1. Cellular aspects of the pathogenesis of lupus nephritis.
Chang A; Clark MR; Ko K
Curr Opin Rheumatol; 2021 Mar; 33(2):197-204. PubMed ID: 33394604
[TBL] [Abstract][Full Text] [Related]
2. The Pathogenesis and Therapeutic Implications of Tubulointerstitial Inflammation in Human Lupus Nephritis.
Clark MR; Trotter K; Chang A
Semin Nephrol; 2015 Sep; 35(5):455-64. PubMed ID: 26573548
[TBL] [Abstract][Full Text] [Related]
3. [Characteristics of serum autoantibodies in patients with lupus nephritis and tubulointerstitial damage].
Zhang L; Chen C; Weng MT; Zheng AP; Su ML; Wang QW; Cai YM
Beijing Da Xue Xue Bao Yi Xue Ban; 2022 Dec; 54(6):1094-1098. PubMed ID: 36533338
[TBL] [Abstract][Full Text] [Related]
4. Bcl-2 as a Therapeutic Target in Human Tubulointerstitial Inflammation.
Ko K; Wang J; Perper S; Jiang Y; Yanez D; Kaverina N; Ai J; Liarski VM; Chang A; Peng Y; Lan L; Westmoreland S; Olson L; Giger ML; Chun Wang L; Clark MR
Arthritis Rheumatol; 2016 Nov; 68(11):2740-2751. PubMed ID: 27159593
[TBL] [Abstract][Full Text] [Related]
5. Vimentin is a dominant target of in situ humoral immunity in human lupus tubulointerstitial nephritis.
Kinloch AJ; Chang A; Ko K; Henry Dunand CJ; Henderson S; Maienschein-Cline M; Kaverina N; Rovin BH; Salgado Ferrer M; Wolfgeher D; Liarski V; Haddon DJ; Utz PJ; Wilson PC; Clark MR
Arthritis Rheumatol; 2014 Dec; 66(12):3359-70. PubMed ID: 25306868
[TBL] [Abstract][Full Text] [Related]
6. The pathogenesis, diagnosis and treatment of lupus nephritis.
Schwartz N; Goilav B; Putterman C
Curr Opin Rheumatol; 2014 Sep; 26(5):502-9. PubMed ID: 25014039
[TBL] [Abstract][Full Text] [Related]
7. Brief Report: Tubulointerstitial Damage in Lupus Nephritis: A Comparison of the Factors Associated With Tubulointerstitial Inflammation and Renal Scarring.
Londoño Jimenez A; Mowrey WB; Putterman C; Buyon J; Goilav B; Broder A
Arthritis Rheumatol; 2018 Nov; 70(11):1801-1806. PubMed ID: 29851285
[TBL] [Abstract][Full Text] [Related]
8. Pathogenesis of kidney disease in systemic lupus erythematosus.
Bagavant H; Fu SM
Curr Opin Rheumatol; 2009 Sep; 21(5):489-94. PubMed ID: 19584729
[TBL] [Abstract][Full Text] [Related]
9. A review of the AURORA and BLISS trials: will it revolutionize the treatment of lupus nephritis?
Asif S; Bargman J; Auguste B
Curr Opin Nephrol Hypertens; 2022 May; 31(3):278-282. PubMed ID: 35249969
[TBL] [Abstract][Full Text] [Related]
10. New insights into the role of renal resident cells in the pathogenesis of lupus nephritis.
Kwok SK; Tsokos GC
Korean J Intern Med; 2018 Mar; 33(2):284-289. PubMed ID: 29320847
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of voclosporin versus placebo for lupus nephritis (AURORA 1): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial.
Rovin BH; Teng YKO; Ginzler EM; Arriens C; Caster DJ; Romero-Diaz J; Gibson K; Kaplan J; Lisk L; Navarra S; Parikh SV; Randhawa S; Solomons N; Huizinga RB
Lancet; 2021 May; 397(10289):2070-2080. PubMed ID: 33971155
[TBL] [Abstract][Full Text] [Related]
12. Lupus nephritis: from pathogenesis to targets for biologic treatment.
Liu Y; Anders HJ
Nephron Clin Pract; 2014; 128(3-4):224-31. PubMed ID: 25401461
[TBL] [Abstract][Full Text] [Related]
13. Pathogenesis of lupus nephritis: the contribution of immune and kidney resident cells.
Bhargava R; Li H; Tsokos GC
Curr Opin Rheumatol; 2023 Mar; 35(2):107-116. PubMed ID: 35797522
[TBL] [Abstract][Full Text] [Related]
14. Lupus nephritis: a critical review.
Borchers AT; Leibushor N; Naguwa SM; Cheema GS; Shoenfeld Y; Gershwin ME
Autoimmun Rev; 2012 Dec; 12(2):174-94. PubMed ID: 22982174
[TBL] [Abstract][Full Text] [Related]
15. Laquinimod delays and suppresses nephritis in lupus-prone mice and affects both myeloid and lymphoid immune cells.
Lourenço EV; Wong M; Hahn BH; Palma-Diaz MF; Skaggs BJ
Arthritis Rheumatol; 2014 Mar; 66(3):674-85. PubMed ID: 24574228
[TBL] [Abstract][Full Text] [Related]
16. Voclosporin: a novel calcineurin inhibitor for the treatment of lupus nephritis.
van Gelder T; Lerma E; Engelke K; Huizinga RB
Expert Rev Clin Pharmacol; 2022 May; 15(5):515-529. PubMed ID: 35763288
[TBL] [Abstract][Full Text] [Related]
17. Diagnostic and prognostic significance of anti-C1q antibodies in systemic lupus erythematosus.
Seelen MA; Trouw LA; Daha MR
Curr Opin Nephrol Hypertens; 2003 Nov; 12(6):619-24. PubMed ID: 14564199
[TBL] [Abstract][Full Text] [Related]
18. Extraglomerular immune complex deposition in lupus nephritis.
Papa V; Brainer J; Henriksen KJ; Cenacchi G; Chang A
Lupus; 2022 Jan; 31(1):19-27. PubMed ID: 34911399
[TBL] [Abstract][Full Text] [Related]
19. B-cell depletion or belimumab or voclosporin for lupus nephritis?
Lei Y; Loutan J; Anders HJ
Curr Opin Nephrol Hypertens; 2021 Mar; 30(2):237-244. PubMed ID: 33186226
[TBL] [Abstract][Full Text] [Related]
20. Phoenix from the flames: Rediscovering the role of the CD40-CD40L pathway in systemic lupus erythematosus and lupus nephritis.
Ramanujam M; Steffgen J; Visvanathan S; Mohan C; Fine JS; Putterman C
Autoimmun Rev; 2020 Nov; 19(11):102668. PubMed ID: 32942031
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
